369 related articles for article (PubMed ID: 26603549)
1. PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT?
Rowe SP; Mana-Ay M; Javadi MS; Szabo Z; Leal JP; Pomper MG; Pienta KJ; Ross AE; Gorin MA
Clin Genitourin Cancer; 2016 Feb; 14(1):e115-8. PubMed ID: 26603549
[No Abstract] [Full Text] [Related]
2. Prospective Comparison of PET Imaging with PSMA-Targeted
Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG
J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Bone Uptake in Bone Scan and Ga-68 PSMA PET/CT Images in Patients with Prostate Cancer.
Acar E; Bekiş R; Polack B
Curr Med Imaging Rev; 2019; 15(6):589-594. PubMed ID: 32008568
[TBL] [Abstract][Full Text] [Related]
4. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [
Werner RA; Bundschuh RA; Bundschuh L; Lapa C; Yin Y; Javadi MS; Buck AK; Higuchi T; Pienta KJ; Pomper MG; Lodge MA; Gorin MA; Rowe SP
Mol Imaging Biol; 2020 Feb; 22(1):190-197. PubMed ID: 31140110
[TBL] [Abstract][Full Text] [Related]
5. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
6. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [
Sahakyan K; Li X; Lodge MA; Werner RA; Bundschuh RA; Bundschuh L; Kulkarni HR; Schuchardt C; Baum RP; Pienta KJ; Pomper MG; Ross AE; Gorin MA; Rowe SP
Mol Imaging Biol; 2020 Feb; 22(1):181-189. PubMed ID: 31115751
[TBL] [Abstract][Full Text] [Related]
7. Semiquantitative Parameters in PSMA-Targeted PET Imaging with
Li X; Rowe SP; Leal JP; Gorin MA; Allaf ME; Ross AE; Pienta KJ; Lodge MA; Pomper MG
J Nucl Med; 2017 Jun; 58(6):942-946. PubMed ID: 27932557
[No Abstract] [Full Text] [Related]
8. Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi.
Gorin MA; Marashdeh W; Ross AE; Allaf ME; Pienta KJ; Pomper MG; Rowe SP
Nucl Med Commun; 2017 Sep; 38(9):795-798. PubMed ID: 28704341
[TBL] [Abstract][Full Text] [Related]
9. Intraindividual Comparison of
Rathke H; Afshar-Oromieh A; Giesel FL; Kremer C; Flechsig P; Haufe S; Mier W; Holland-Letz T; De Bucourt M; Armor T; Babich JW; Haberkorn U; Kratochwil C
J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410
[TBL] [Abstract][Full Text] [Related]
10. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG
Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970
[TBL] [Abstract][Full Text] [Related]
11. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Szabo Z; Mena E; Rowe SP; Plyku D; Nidal R; Eisenberger MA; Antonarakis ES; Fan H; Dannals RF; Chen Y; Mease RC; Vranesic M; Bhatnagar A; Sgouros G; Cho SY; Pomper MG
Mol Imaging Biol; 2015 Aug; 17(4):565-74. PubMed ID: 25896814
[TBL] [Abstract][Full Text] [Related]
12. A Prospective Comparison of
Harmon SA; Bergvall E; Mena E; Shih JH; Adler S; McKinney Y; Mehralivand S; Citrin DE; Couvillon A; Madan RA; Gulley JL; Mease RC; Jacobs PM; Pomper MG; Turkbey B; Choyke PL; Lindenberg ML
J Nucl Med; 2018 Nov; 59(11):1665-1671. PubMed ID: 29602821
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[
Sonni I; Minamimoto R; Baratto L; Gambhir SS; Loening AM; Vasanawala SS; Iagaru A
Mol Imaging Biol; 2020 Apr; 22(2):397-406. PubMed ID: 31236756
[TBL] [Abstract][Full Text] [Related]
14. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on
Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Leal JP; Higuchi T; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP
J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304
[TBL] [Abstract][Full Text] [Related]
15. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
16. Comparison between
Liu Y; Dong Y; Liu J; Zhang X; Lin M; Xu B
Prostate; 2021 Dec; 81(16):1329-1336. PubMed ID: 34516670
[TBL] [Abstract][Full Text] [Related]
17.
Wondergem M; van der Zant FM; Knol RJJ; Lazarenko SV; Pruim J; de Jong IJ
J Nucl Med; 2017 Nov; 58(11):1797-1804. PubMed ID: 28450569
[TBL] [Abstract][Full Text] [Related]
18. Correlation of PSMA-Targeted
Tosoian JJ; Gorin MA; Rowe SP; Andreas D; Szabo Z; Pienta KJ; Pomper MG; Lotan TL; Ross AE
Clin Genitourin Cancer; 2017 Feb; 15(1):e65-e68. PubMed ID: 27751686
[No Abstract] [Full Text] [Related]
19. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
20. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).
Ray Banerjee S; Pullambhatla M; Foss CA; Falk A; Byun Y; Nimmagadda S; Mease RC; Pomper MG
J Med Chem; 2013 Aug; 56(15):6108-21. PubMed ID: 23799782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]